Literature DB >> 23756852

Omeprazole enhances the colonic expression of the Mg(2+) transporter TRPM6.

A L L Lameris1, M W Hess, I van Kruijsbergen, J G J Hoenderop, R J M Bindels.   

Abstract

Proton pump inhibitors (PPIs) are potent blockers of gastric acid secretion, used by millions of patients suffering from gastric acid-related complaints. Although PPIs have an excellent safety profile, an increasing number of case reports describe patients with severe hypomagnesemia due to long-term PPI use. As there is no evidence of a renal Mg²⁺ leak, PPI-induced hypomagnesemia is hypothesized to result from intestinal malabsorption of Mg²⁺. The aim of this study was to investigate the effect of PPIs on Mg ²⁺homeostasis in an in vivo mouse model. To this end, C57BL/6J mice were treated with omeprazole, under normal and low dietary Mg²⁺ availability. Omeprazole did not induce changes in serum Mg²⁺ levels (1.48 ± 0.05 and 1.54 ± 0.05 mmol/L in omeprazole-treated and control mice, respectively), urinary Mg²⁺ excretion (35 ± 3 μmol/24 h and 30 ± 4 μmol/24 h in omeprazole-treated and control mice, respectively), or fecal Mg²⁺ excretion (84 ± 4 μmol/24 h and 76 ± 4 μmol/24 h in omeprazole-treated and control mice, respectively) under any of the tested experimental conditions. However, omeprazole treatment did increase the mRNA expression level of the transient receptor potential melastatin 6 (TRPM6), the predominant intestinal Mg²⁺ channel, in the colon (167 ± 15 and 100 ± 7 % in omeprazole-treated and control mice, respectively, P < 0.05). In addition, the expression of the colonic H⁺,K⁺-ATPase (cHK-α), a homolog of the gastric H⁺,K⁺-ATPase that is the primary target of omeprazole, was also significantly increased (354 ± 43 and 100 ± 24 % in omeprazole-treated and control mice, respectively, P < 0.05). The expression levels of other magnesiotropic genes remained unchanged. Based on these findings, we hypothesize that omeprazole inhibits cHK-α activity, resulting in reduced extrusion of protons into the large intestine. Since TRPM6-mediated Mg²⁺absorption is stimulated by extracellular protons, this would diminish the rate of intestinal Mg²⁺ absorption. The increase of TRPM6 expression in the colon may compensate for the reduced TRPM6 currents, thereby normalizing intestinal Mg²⁺ absorption during omeprazole treatment in C57BL/6J mice, explaining unchanged serum, urine, and fecal Mg²⁺ levels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23756852     DOI: 10.1007/s00424-013-1306-0

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  38 in total

1.  [Hypomagnesemia related to the use of omeprazole with negative result for mutation in the TRPM6 gene].

Authors:  Francisco José Fernández-Fernández; Pascual Sesma; Tamara Caínzos-Romero; Lucía Ferreira
Journal:  Med Clin (Barc)       Date:  2010-11-02       Impact factor: 1.725

2.  Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole.

Authors:  F J Fernández-Fernández; P Sesma; T Caínzos-Romero; L Ferreira-González
Journal:  Neth J Med       Date:  2010-10       Impact factor: 1.422

Review 3.  The gastric H,K ATPase as a drug target: past, present, and future.

Authors:  George Sachs; Jai Moo Shin; Olga Vagin; Nils Lambrecht; Iskandar Yakubov; Keith Munson
Journal:  J Clin Gastroenterol       Date:  2007-07       Impact factor: 3.062

4.  EGF increases TRPM6 activity and surface expression.

Authors:  Stéphanie Thebault; R Todd Alexander; Wouter M Tiel Groenestege; Joost G Hoenderop; René J Bindels
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

5.  The human non-gastric H,K-ATPase has a different cation specificity than the rat enzyme.

Authors:  Herman G P Swarts; Jan B Koenderink; Peter H G M Willems; Jan Joep H H M De Pont
Journal:  Biochim Biophys Acta       Date:  2006-10-26

Review 6.  Molecular determinants of magnesium homeostasis: insights from human disease.

Authors:  R Todd Alexander; Joost G Hoenderop; René J Bindels
Journal:  J Am Soc Nephrol       Date:  2008-06-18       Impact factor: 10.121

Review 7.  TRPM6 and TRPM7--Gatekeepers of human magnesium metabolism.

Authors:  Karl P Schlingmann; Siegfried Waldegger; Martin Konrad; Vladimir Chubanov; Thomas Gudermann
Journal:  Biochim Biophys Acta       Date:  2007-04-03

8.  Severe hypomagnesaemia in long-term users of proton-pump inhibitors.

Authors:  T Cundy; A Dissanayake
Journal:  Clin Endocrinol (Oxf)       Date:  2008-01-23       Impact factor: 3.478

Review 9.  Hypomagnesaemia due to use of proton pump inhibitors--a review.

Authors:  M T Kuipers; H D Thang; A B Arntzenius
Journal:  Neth J Med       Date:  2009-05       Impact factor: 1.422

10.  Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7.

Authors:  Mingjiang Li; Jianmin Jiang; Lixia Yue
Journal:  J Gen Physiol       Date:  2006-05       Impact factor: 4.086

View more
  24 in total

1.  Proton pump inhibitor associated hypomagnasaemia - a cause for concern?

Authors:  Joe Begley; Trevor Smith; Kirsty Barnett; Paul Strike; Adnan Azim; Claire Spake; Tristan Richardson
Journal:  Br J Clin Pharmacol       Date:  2016-01-25       Impact factor: 4.335

2.  Extreme hypomagnesemia: characteristics of 119 consecutive inpatients.

Authors:  Geoffrey Cheminet; Gabrielle Clain; Anne-Sophie Jannot; Brigitte Ranque; Amélie Passeron; Adrien Michon; Gonzalo De Luna; Jean-Luc Diehl; Stéphane Oudard; Christophe Cellier; Alexandre Karras; Benoit Vedié; Caroline Prot-Bertoye; Jacques Pouchot; Jean-Benoît Arlet
Journal:  Intern Emerg Med       Date:  2018-06-27       Impact factor: 3.397

3.  Gastric acid-dependent diseases: a twentieth-century revolution.

Authors:  George Sachs; Jai Moo Shin; Keith Munson; David R Scott
Journal:  Dig Dis Sci       Date:  2014-07       Impact factor: 3.199

4.  Uromodulin regulates renal magnesium homeostasis through the ion channel transient receptor potential melastatin 6 (TRPM6).

Authors:  Mingzhu Nie; Manjot S Bal; Jie Liu; Zhufeng Yang; Carolina Rivera; Xue-Ru Wu; Joost G J Hoenderop; René J M Bindels; Denise K Marciano; Matthias T F Wolf
Journal:  J Biol Chem       Date:  2018-08-23       Impact factor: 5.157

Review 5.  Proton-pump inhibitor-induced hypomagnesemia: Current research and proposed mechanisms.

Authors:  Jeffrey H William; John Danziger
Journal:  World J Nephrol       Date:  2016-03-06

6.  P2X4 receptor regulation of transient receptor potential melastatin type 6 (TRPM6) Mg2+ channels.

Authors:  Jeroen H F de Baaij; Maxime G Blanchard; Marla Lavrijsen; Jens Leipziger; René J M Bindels; Joost G J Hoenderop
Journal:  Pflugers Arch       Date:  2014-01-12       Impact factor: 3.657

Review 7.  Proton-pump inhibitors: understanding the complications and risks.

Authors:  Peter Malfertheiner; Arne Kandulski; Marino Venerito
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

8.  Omeprazole suppressed plasma magnesium level and duodenal magnesium absorption in male Sprague-Dawley rats.

Authors:  Narongrit Thongon; Jirawat Penguy; Sasikan Kulwong; Kanyanat Khongmueang; Matthana Thongma
Journal:  Pflugers Arch       Date:  2016-11-19       Impact factor: 3.657

9.  The inhibitory role of purinergic P2Y receptor on Mg2+ transport across intestinal epithelium-like Caco-2 monolayer.

Authors:  Narongrit Thongon; Siriporn Chamniansawat
Journal:  J Physiol Sci       Date:  2018-07-21       Impact factor: 2.781

10.  The Effects of pH on the Structure and Bioavailability of Imidazobenzodiazepine-3-Carboxylate MIDD0301.

Authors:  M S Rashid Roni; Guanguan Li; Brandon N Mikulsky; Daniel E Knutson; Md Yeunus Mian; Nicolas M Zahn; James M Cook; Douglas C Stafford; Leggy A Arnold
Journal:  Mol Pharm       Date:  2020-02-26       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.